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Hypertrophic Cardiomyopathy (HCM) 
 
Prevalence of HCM 
 
HCM is inherited as an autosomal dominant disease in 
both humans (Liu et al., 1993; Maron et al., 2003) and cats 
(Meurs et al., 2007; Meurs et al., 2005). It is the most 
prevalent cardiomyopathy disease in both species; however, 
several factors preclude accurate determination of the 
disease frequency. It has been estimated to affect 0.1 - 0.2% 
of the human population and is the leading cause of sudden 
cardiac death in adolescents (including competitive athletes) 
(Maron et al., 1995). In cats the prevalence is high and it is 
estimated closed to 16% of the overtly healthy cat 
population are affected (Cote et al., 2004; Paige et al., 
2009; Riesen et al., 2007a). A retrospective 
echocardiographic study reported that 57.5% of cats 
initially diagnosed as idiopathic cardiomyopathy (n = 106) 
were found to have HCM (Ferasin et al., 2003).  
HCM is a disease of young-to-middle age cats between 
8 months to 16 year (mean of onset around 6.5 year) (Kraus 
et al., 1999; Nakagawa et al., 2002). The youngest 
documented was 2 months old (Fujii et al., 2001) and was 
commonly observed in males (Fujii et al., 2001; Granstrom 
et al., 2011; Liu et al., 1981; Riesen et al., 2007a; Tilley et 
al., 1977), a pattern which is not seen in humans. Male cats 
were also observed predisposed to HCM earlier in life and 
with a more aggressive development of the disease (Atkins 
et al., 1992; Rush et al., 2002), compared to female cats. 
Generally, cats are a sedentary animal by nature but 
stressful situations (e.g. cat fights or chased by dog – 
increased sympathetic activity of the heart), may induce 
sudden death in cats with asymptomatic HCM (Kittleson 
and Kienle, 1998). A cross-sectional echocardiographic 
study identified a high frequency of 8 - 10% HCM amongst 
overtly healthy cats (Riesen et al., 2007a), which suggested 
that substantial changes to the heart were apparent well 
before any clinical signs were observed. This asymptomatic 
incidence of HCM partially explains episodes of sudden 
death or aortic thromboembolism that occurs in apparently 
young healthy cats without any obvious clinical signs (Baty 
et al., 2001; Cote et al., 2004; Liu and Tilley, 1980; Riesen 
et al., 2007b). Two large retrospective studies reported that 
the median survival time for cats presented with aortic 
thromboembolism, congestive heart failure and  
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asymptomatic cats were between 2 to 6 months, 6 to 18 
months and 3 to 5 years, respectively (Atkins et al., 1992; 
Rush et al., 2002).  
 
Genetic factors of HCM 
 
Abnormalities in the encoding sarcomeric proteins 
identified in HCM patients have led to a theory that it is a 
disease of contractile sarcomeric proteins (Marian and 
Roberts, 2001). HCM in humans is caused by a genetic 
mutation in one of the genes that encode for the sarcomeric 
proteins including β-myosin heavy chain (MyHC), cardiac 
troponin T and myosin binding protein C gene (MyBP-C) 
(Marian and Roberts, 2001; Maron, 2002). Other genes that 
accounted for a minority of human HCM cases were cardiac 
troponin I, regulatory and essential myosin light chain, titin, 
α-tropomysin, α-actin and α-myosin heavy chain (Ommen 
and Nishimura, 2004). In human, HCM is inherited, usually 
as a heterogeneous autosomal dominant trait, in at least 2/3 
of all HCM cases (Marian and Roberts, 2001; Solomon et 
al., 1990). To date, more than 1000 different mutations have 
been identified within 13 myofilament-related genes in 
human (Alcalai et al., 2008; Davies and Krikler, 1994; 
Solomon et al., 1990). 
In cats, recent studies in Maine Coon and Ragdoll 
breeds have identified defects in the same sarcomeric 
protein genes, MyBP-C, but in different locations (Kittleson 
et al., 1998; Meurs et al., 2008; Meurs et al., 2007; Meurs 
et al., 2005), heritable in an autosomal dominant pattern 
(Baty and Walkins, 1998; Fananapazir and Epstein, 1994; 
Kittleson et al., 1999; Meurs et al., 2005). In addition to 
these breeds, there is anecdotal evidence of the familial 
heritability of HCM in other breeds, including Persian, 
British Shorthair, Norwegian Forest Cat, Turkish Van, 
Scottish Fold, Siberian, Sphynx and others (Granstrom et 
al., 2011; Meurs et al., 2009; Tilley et al., 2008), although 
the exact genetic cause in these breeds have not been well 
studied. The familial nature of HCM has also been reported 
in domestic (mixed-breed) cats (Kraus et al., 1999; 
Nakagawa et al., 2002). A long term observation on the 
progression of HCM in a family of domestic shorthair cat 
has been documented (Baty et al., 2001).  
HCM in Maine Coon cats closely resembles human 
familial HCM in terms of mode of inheritance, phenotypic 
expression and disease course (Fananapazir and Epstein, 
1994; Kittleson et al., 1999; Meurs et al., 2005). Recent 
study have found that the MyBP-C gene mutation in Maine 
Coon cats is breed specific and may not appears to be 




associated with the familial HCM in other breed of cats. 
The mutation is inherited with incomplete penetrance 
(heterozygous) with variable expressivity where not all cats 
with the mutation will show the disease or the severity of 
the disease may varies among cats (Figure 1) (Carlos 
Sampedrano et al., 2009; Lyons, 2010; Meurs et al., 2005). 
Carlos Sampedrano et al. (2009) identified 18% of Maine 
Coon cats (n = 8/44) with MyBP-C has HCM, hence not all 
cats with the identified gene developed HCM. The actual 
prevalence may have been underestimated and probably a 
long-term follow-up would accurately establish the onset of 
disease and its effects on all ages of cats. It was also 
suggested that there are likely more than one mutation 
responsible for HCM in this breed (Carlos Sampedrano et 
al., 2009). In Ragdoll cats, the substitution mutation 
identified in the MyBP-C, differs from the Maine Coon cats 
because the mutation is located in a different region. 
Therefore, Maine Coon and Ragdoll cats’ mutations were 
unlikely inherited from a common ancestor. The mode of 
inheritance in Ragdoll cats is yet to be identified and this 
breed-specific mutation has not been identified in other 
breeds of cats. In Ragdoll cats, it was shown that the 
homozygous cats appeared to be very severely affected, 
often before 2 years of age and the heterozygous cats 
appeared to have a milder form of the disease (Meurs et al., 
2007). 
In summary, the identification of the first sarcomeric 
gene mutation, MyBP-C in Maine Coon cats is highly 
significant and supports a role for cats as an alternative to 
transgenic mice as a animal model of human familial HCM 


















Unaffected male/female       / Affected male/female    -------- Mated 
The typical features of this mode of inheritance are that it is present in every generation 
 
Figure 1: Example of a colony of cats with familial HCM [an autosomal dominant inheritance with incomplete penetrance 
(heterozygous)] 
 
Pathogenesis and progression of HCM 
 
It is a primary disorder of the myocardium 
characterised by concentric left ventricular hypertrophy, can 
be further described as mild-to-severe (thicken wall of a 
normal-to-small chamber size) (Kittleson and Kienle, 
1998). To distinguish either: mild hypertrophy from normal, 
mild-to-moderate hypertrophy, severe hypertrophy or 
secondary due to other abnormalities are often not easy 
(Boon, 1998; Fox et al., 1999; Moise et al., 1986). HCM is 
phenotypically heterogeneous and no single distribution of 
left ventricular hypertrophy is typical of the disease 
(Kittleson and Kienle, 1998). Many have compared and 
correlated echocardiography findings with other diagnostic 
methods such as electrocardiography, necropsy, 
histopathology and computed magnetic resonant imaging to 
correlated the site or severity of hypertrophy and clinical 
findings (Fox, 2003; Sato et al., 1998).  
HCM consist of two forms; obstructive and non-
obstructive. Hypertrophy obstructive cardiomyopathy 
(HOCM) occurs when the hypertrophied basilar  
 
 
interventricular septum impinges and results in narrowing 
of the left ventricular outflow tract. The mitral valve is 
pushed into the outflow tract causing systolic anterior 
motion (SAM) of the mitral valve causing further 
obstruction of the outflow tract. At the onset of SAM of the 
mitral valve in HCM patients, the pushing force of flow is 
caused by the dominant hydrodynamic force (Sherrid et al., 
2000), although the Venturi force are present in the outflow 
tract but does not contribute to the mechanism of SAM. 
Hence, the obstruction may be either dynamic, fixed or both 
(Boon, 1998; French, 2008; Takemura et al., 2003). SAM 
of the mitral valve is infrequently reported in cats with 
HCM but one isolated report by Fox et al. (1995) found that 
SAM was a common abnormality identified in 67% of the 
HCM cats (n=46). However, this condition may not present 
in all HCM cats and some cats may develop this condition 
before any evidence of wall thickening or some cats may 
have SAM of the mitral valve as a primary disease (Fox et 
al., 1995; Kittleson and Kienle, 1998; Klues et al., 1993) 
and similar has been widely studied and reported in HCM 
patients (Klues et al., 1993; Spirito and Maron, 1984). 




Therefore, it is important to distinguish between 
obstructive and non-obstructive forms of HCM, as clinical 
decisions depend on the presence or absence of outflow 
obstruction (Kittleson and Kienle, 1998). SAM of the mitral 
valve produce two abnormalities where: (i) it obstructs 
blood flows out of the left ventricle in systole (dynamic 
sub-aortic stenosis) causing an increase blood flow velocity 
through the sub-aortic region producing a turbulence and; 
(ii) the septal leaflet drawn out from its normal position 
creates a mitral regurgitation due to SAM (Kittleson and 
Kienle, 1998). Dynamic outflow tract obstruction if severe 
will be a stimulus for concentric hypertrophy and 
potentially worsen left ventricular diastolic dysfunction. 
Hence, coupled with other structural pathological change 
(i.e. myocardial fibre disarray, myocardial fibrosis), it may 





Cats with severe HCM have severe thickening of the 
left ventricular myocardium [the interventricular septum 
(IVS) and left ventricular free wall (LVFW)], papillary 
muscle hypertrophy and left atrium enlargement with 
possible thrombus present. The left ventricular chamber is 
smaller than normal due to the inwards myocardial 
thickening into the left ventricular cavity (Cesta et al., 2005; 
Fox, 2003; Liu et al., 1981; Liu et al., 1993; Tilley et al., 
1977). The distributions of the myocardium thickness in 
most cases may not be the same. The IVS and the LVFW 
are equally thickened (symmetric hypertrophy) in most cats 
with severe HCM. Other cats may have significantly thicker 
IVS compared to the LVFW or vice versa. Cats with mild-
to-moderate HCM have lesser myocardial wall thickness, 
hypertrophy papillary muscle and probably a normal size of 
left ventricular and atrium chamber (Fox et al., 1999; 
Kittleson and Kienle, 1998; Tilley et al., 2008). Heart 
weight was reported to be a useful indicator for disease 
severity or to identify hearts with hypertrophy grossly. The 
heart weight in relation to the body weight has been 
reported to be 4.8 ± 1.8 g/kg in healthy cats versus 6.0 ± 




HCM has a wide range of histopathological 
abnormalities but myocardial fibre disarray is a distinctive 
hallmark of HCM. The myocytes are arranged in chaotic, 
disorganised patterns at oblique and/or perpendicular angle 
which appeared in a bizarre disorganised cellular 
architecture (Baty et al., 2001; Fox, 2003; Kittleson and 
Kienle, 1998; Liu et al., 1993; Nakagawa et al., 2002; 
Tilley et al., 1977). Other histopathological findings are 
hypertrophied myocytes, increased collagen deposition 
resulting interstitial fibrosis and abnormalities of the 
intramyocardial small vessels (Cesta et al., 2005; Fox, 
2003; Liu et al., 1993; Nakagawa et al., 2002; Varnava et 
al., 2000). It is likely that these abnormal structural changes 
disrupt the transmission of electrophysiology impulses 
predisposing the diseased heart to diastolic dysfunction and 
ventricular tachyarrhythmia (Fox, 2003; Kittleson and 
Kienle, 1998; Liu et al., 1981; Liu et al., 1993; Tilley et al., 
1977). The frequency of each abnormality observed varied 
between HCM cats (Liu et al., 1993). Liu et al. (1981) 
found 25% of the HCM cats (n=51) observed with 
asymmetric left ventricular hypertrophy had myocardial 
fibre disarray in the IVS. In other HCM hearts, only 
myocyte hypertrophy was evident or some had moderate-to-
severe interstitial. Replacement fibrosis was present in 
about 20 - 40% of HCM cases (Liu et al., 1993). The 
histopathological findings differ between HCM hearts 
probably due to cardiac remodelling which occurs at 
different stages of the disease, maybe depending on the 
extent of the damage. Hence, whether the asymptomatic 
cats with HCM have similar histopathological findings at 
the early stage despite detectable functional changes is 




The pathogenesis of HCM in both humans and cats, to our 
knowledge is still not fully understood. It is a known 
genetic cardiovascular disease due to the mutations in genes 
encoding proteins of the cardiac sarcomere, but the 
molecular pathogenesis that leads to the development of 
hypertrophy and the variability in the common pathological 
phenotypes expression still remain unknown (Abbott, 2010; 
Braundwald et al., 2012; Lind et al., 2006; Marian, 2000; 
Maron et al., 2009). A mouse model has recently been used 
to gain greater understanding of this complex genetic 
disorder (Berul et al., 2001; Geisterfer-Lowrance et al., 
1996; James et al., 1998; Prabhakar et al., 2003; Shephard 
and Semsarian, 2009; Welikson et al., 1999) as studies of 
molecular and pathophysiological mechanisms in cats or 
human HCM patients is difficult, particularly since the 
disease is often well established before diagnosis, especially 
 
Figure 2: Representative photomicrographs of left ventricular 
myocardium from a cat with terminal HCM demonstrating 
myocardial fibre disarray (H&E stain; x40 magnification) 




in cats. Pathophysiological changes and/or dysfunction 
presence at the early stage of HCM in cats well before the 
clinical sign was observed but actual mechanism is still 
widely debated. The genetic mutation or the 
pathophysiological mechanism is a trigger of the HCM is 
still unknown, to our knowledge.  
What is understood now are that in any particular HCM 
cat, one or more of the pathophysiological changes and 
dysfunctions may occur including: (i) left ventricular 
diastolic dysfunction; (ii) ventricular and superventricular 
tachyarrhythmias; and (iii) myocardial ischemia and fibrosis 
(Kittleson and Kienle, 1998; Maron et al., 2009; Tilley et 
al., 2008). Coupled with those important derangements, 
there are other under-recognised emerging 
pathophysiological concerns such as the possible presences 
of myocarditis (Bayes-Genis, 2007) and autonomic nervous 
dysfunction (Morner et al., 2005) to our knowledge has not 
been given emphasis in cats with HCM.  
 
Left ventricular diastolic dysfunction 
 
The main functional implication in cats with HCM is 
diastolic dysfunction (Fox et al., 1999; Kittleson and 
Kienle, 1998; Tilley et al., 2008). The pathological changes 
of the concentric left ventricular hypertrophy from cardiac 
remodelling increased myocardial stiffness, increased end 
diastolic filling pressure and impaired early diastolic 
relaxation (Abbott, 2000; Fox, 2007; Liu et al., 1993).  
In HCM, diastolic function is compromised by several 
mechanisms. Ventricular compliance is reduced as a result 
of left ventricular hypertrophy and small arterial changes 
that impair left ventricular perfusion, causing myocardial 
ischemia, necrosis and replacement fibrosis (Kitamura et 
al., 2001; Kittleson and Kienle, 1998). Compliance is 
further compromised by myocardial fibre disarray which 
has been shown as the most important factor related to 
diastolic dysfunction in humans HCM (Osato et al., 1989) 
but assumed to contribute similar consequences in cats with 
HCM (Kittleson et al., 1999). Besides that, impaired 
sarcolemmal calcium channel regulation and impaired 
calcium uptake by the sarcoplasmic reticulum leads to 
increased intracellular calcium concentration and impaired 
active relaxation (Gwathmey et al., 1991; Opie, 2004).  
 
Ventricular and supraventricular tachyarrhythmias 
 
Correlation between left ventricular hypertrophy and 
arrhythmogenic sudden death is well established not only in 
HCM, but in other conditions that contribute to left 
ventricular hypertrophy (i.e. hypertensive and aortic 
stenosis) (Douglas and Tallant, 1991; Piorecka-Makula and 
Werner, 2009; Wolk, 2000). The most consistently 
observed abnormality that predisposed to arrhythmia is 
early or delayed afterdepolarisation and triggered activity 
leading to prolong action potential durations and 
refractoriness. In addition, non-uniform prolongation of the 
action potential may lead to increased dispersion of 
repolarisation or refractoriness and favouring re-entry in the 
heart (Levick, 2003; Strickland, 1998; Wolk, 2000). In 
humans with HCM, the disorganised cellular architecture, 
myocardial fibrosis and scarring due to cardiac remodelling 
has been suspected as an arrhythmogenic substrate 
predisposing to the life-threatening electrical instability 
(Marian and Roberts, 2001; Ommen and Nishimura, 2004; 
Spirito et al., 1987). 
Spirito et al. (1987) documented a strong association of 
severe-to-moderate left ventricular hypertrophy with 
significantly increased occurrences of ventricular 
tachycardia in HCM patients. Cats with a history of 
episodic collapse or dyspnoea diagnosed with HCM were 
identified with a high frequency of severe ventricular 
arrhythmias (i.e. ventricular premature complexes, 
ventricular bigeminy, ventricular tachycardia, 
supraventricular tachycardia, supraventricular premature 
complex) (Bright and Cali, 2000; Ferasin et al., 2003; 
Goodwin et al., 1992). 
 
Myocardial ischaemic and fibrosis  
 
Application of positron emission topography and 
cardiovascular magnetic resonant has allowed evaluation of 
active myocardial ischemia as a determinant of progressive 
heart failure in human HCM patients (Harris et al., 2006; 
O'Gara et al., 1987; Olivotto et al., 2004). The combination 
of increased left ventricular wall thickness (increased 
myocardial oxygen demand) and decreased capillary 
network (decreased myocardial oxygen supply) will 
increase heart rate and afterload, while decreased perfusion 
may predispose to myocardial ischemia(Ommen and 
Nishimura, 2004).  
Presence of myocardial ischemia due to microvascular 
dysfunction in HCM has been suggested as an important 
pathophysiologic component of the disease progression 
(Maron et al., 2009). Cats with HCM have coronary 
remodelling (arteriosclerosis or “small vessel disease”) 
similar to that described in humans with HCM (Baty et al., 
2001; Nakagawa et al., 2002; Takemura et al., 2003). Liu et 
al. (1993) identified intramural coronary arteriosclerosis in 
75% (38/51) of cats diagnosed with HCM. Both, Varnava et 
al. (2002) and Liu et al. (1993) described a common finding 
and relate that the intramural coronary arteriosclerosis are 
particularly prominent in tissue sections with moderate-to-
severe fibrosis. There may therefore be a relationship 
between arteriosclerosis and myocardial fibrosis. With 
compromised blood flow in small vessels triggering 
myocardial ischemia, with subsequent cell death (necrosis) 
and scarring (fibrosis) affecting the clinical course of the 
disease. 
Varnava et al. (2000) proposed that myocardial fibre 
disarray was a direct response to the functional and 
structural abnormalities of the mutated sarcomeric protein, 
although the authors also considered that fibrosis and small 
vessel disease were secondary response unrelated to 
disarray. Myocardial ischemia has been linked to 




ventricular tachycardia and sudden death (Wolk, 2000) and 
its presence in the early stages of HCM may actually be a 
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